FactorPad
Build a Better Process

Stock Risk Measures for Fate Therapeutics Inc

A quantitative factor review as of June 30, 2021.
  1. Company Info - Description, identity and sector data.
  2. Share Data - Stock earnings and key dates.
  3. Market Risk - Beta, size, liquidity and momentum measures.
  4. Financial Risk - Earnings and dividends.
face pic by Paul Alan Davis, CFA
Updated: July 06, 2021
See how we arrive at an overall risk score of 54 for FATE below.

/ factorpad.com / stocks / f24wjp.html


An ad-free and cookie-free website.


FATE Risk Report

Overview

Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Fate Therapeutics Inc. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.

We show how FATE stock compares to 2,000+ US-based stocks, and to peers in the Manufacturing sector and Biological Product (except Diagnostic) Manufacturing industry.

Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.

Company Info

Business Description

Company logo Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmuneā„¢, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.

Identity

Sector and Industry

Share Data

Shares

Earnings and Dividends

Market Risk Measures

Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.

Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.

Systematic Risk

Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)

Company Size

Stocks with higher market capitalization often have lower risk. (↑↓)

Trading Liquidity

Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)

Price Momentum

Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)

Financial Risk Measures

Style risk factors often include measures of profitability and payout levels.

Earnings Yield

Companies with higher earnings generally provide lower risk. (↑↓)

Dividend Yield

Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)

/ factorpad.com / stocks / f24wjp.html


FATE stock risk
FATE THERAPEUTICS INC stock beta
FATE risk report
FATE f24wjp
FATE risk analysis
FATE volatility
FATE THERAPEUTICS INC credit risk
FATE liquidity risk
FATE leverage
FATE valuation
FATE systematic risk
FATE specific risk
FATE THERAPEUTICS INC volatility
FATE analysis
FATE financial ratio

A newly-updated free resource. Connect and refer a friend today.